MedKoo Cat#: 522374 | Name: ABE171

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ABE171, also known as NVP-ABE171, is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities. NVP-ABE171 inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D with respective IC(50) values of 602, 34, 1230, and 1.5 nM. In human cells, NVP-ABE171 inhibited the eosinophil and neutrophil oxidative burst, the release of cytokines by T cells, and the tumor necrosis factor-alpha release from monocytes, in the nanomolar range. NVP-ABE171 inhibited the airway neutrophil influx and activation with an ED(50) in the range of 3 mg/kg. NVP-ABE171 shows activity both in vitro on human inflammatory cells and in vivo in animal models of lung inflammation.

Chemical Structure

ABE171
ABE171
CAS# 426268-06-6

Theoretical Analysis

MedKoo Cat#: 522374

Name: ABE171

CAS#: 426268-06-6

Chemical Formula: C21H12N4O3

Exact Mass: 368.0909

Molecular Weight: 368.35

Elemental Analysis: C, 68.48; H, 3.28; N, 15.21; O, 13.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ABE171; ABE-171; ABE 171; NVP-ABE171; NVP-ABE-171; NVP-ABE 171.
IUPAC/Chemical Name
4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid
InChi Key
IALXIRPKVRUJQO-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H12N4O3/c26-21(27)13-5-3-12(4-6-13)17-10-14-2-1-9-22-19(14)20(23-17)15-7-8-16-18(11-15)25-28-24-16/h1-11H,(H,26,27)
SMILES Code
O=C(O)C1=CC=C(C2=NC(C3=CC4=NON=C4C=C3)=C5N=CC=CC5=C2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 368.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Powers GL, Hammer KD, Domenech M, Frantskevich K, Malinowski RL, Bushman W, Beebe DJ, Marker PC. Phosphodiesterase 4D inhibitors limit prostate cancer growth potential. Mol Cancer Res. 2015 Jan;13(1):149-60. doi: 10.1158/1541-7786.MCR-14-0110. Epub 2014 Aug 22. PubMed PMID: 25149359; PubMed Central PMCID: PMC4312503. 2: Tigani B, Cannet C, Zurbrugg S, Schaeublin E, Mazzoni L, Fozard JR, Beckmann N. Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging. Br J Pharmacol. 2003 Sep;140(2):239-46. Epub 2003 Aug 18. PubMed PMID: 12970099; PubMed Central PMCID: PMC1574026. 3: Trifilieff A, Wyss D, Walker C, Mazzoni L, Hersperger R. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther. 2002 Apr;301(1):241-8. PubMed PMID: 11907180.